Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The combination of high blood pressure and having central obesity is an increasing important factor for heart disease in men and women. It can also lead to the early development of hardening of the arteries and increased risk of a stroke. This study will analyze patients' genetic make up to identify who may be at greater risk for heart disease and strokes in relationship to high blood pressure and central obesity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Characterization of Brachial Arterial t-PA Release, Endothelial Function, Obesity and Inflammation

NCT00780481

Obesity

TERMINATED NA

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

NCT05009862

Peripheral Arterial Disease

ACTIVE_NOT_RECRUITING PHASE4

Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging

NCT02114697

Atherosclerosis

TERMINATED PHASE4

Platelet PAR-1 Activation in Health and Diabetes

NCT04280549

Type 2 Diabetes Healthy

COMPLETED

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)

NCT03626662

Cardiovascular Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Obesity is an increasingly important risk factor for cardiovascular disease in men and women and is associated with the premature development of atherosclerosis, and increased risk of stroke. A classical perspective of cardiovascular risk does not adequately explain all of the cardiovascular events associated with obesity. Elevated plasma levels of plasminogen activator inhibitor type I (PAI-1) are one of the biochemical hallmarks for obesity and likely contribute the increased risk of atherothrombotic events in patients with obesity. The central hypothesis of this proposal is that the increased risk of atherothrombotic events in patients with obesity. The central hypothesis of this proposal is that vascular PAI-1 excess promotes the development of intravascular thrombosis. We will test the hypothesis that secreted factors from adipocytes have autocrine, paracrine and endocrine effects that have a deleterious effect on the fibrinolytic system, either by enhancing PAI-1 production or impairing endothelial t-PA release. From a public health perspective, there is no greater threat to America's cardiovascular health than the epidemic of obesity. It is anticipated that this study will provide new insights nto the molecular mechanisms that contribute to the development of fibrinolytic dysfunction and cardiovascular disease in obesity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome X

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment A

Eplerenone (study drug)

Group Type ACTIVE_COMPARATOR

Eplerenone

Intervention Type DRUG

5 mg x 1 week followed by 10 mg x 9 weeks.

Treatment B

Ramipril

Group Type ACTIVE_COMPARATOR

Ramipril

Intervention Type DRUG

Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Eplerenone

5 mg x 1 week followed by 10 mg x 9 weeks.

Intervention Type DRUG

Ramipril

Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Inspra

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or females between the ages of 18 to 65 years of age.
* Documented diagnosis for the metabolic syndrome:
* Subjects with hypertension (SP\>130mmHg)
* Subjects with central obesity (females waist \>35"; males waist \>40")
* Subjects with dyslipidemia (HDL \<40mg/dl, triglycerides \> 150 mg/dl)
* Subjects who are insulin resistance (fasting glucose \>100mg/dl)

Exclusion Criteria

* Subjects who smoke
* Women who are pregnant (confirmed by urine beta-HCG).
* Women who are breast feeding
* Subjects with documentation of the following health risk:

* Subjects with serum creatinine \>2.0 mg/dl (males), \>1.8 mg/dl (females)
* Subjects whose creatinine clearance \< 50 mls/min
* Subjects with serum potassium \>5.5mEql
* Subjects with Type 2 diabetes with microalbuminuria (spot urine protein/creatinine ration \>0.2)
* Subjects who are currently taking the following medications:
* Warfarin

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes